|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2005-11-18
|
|
pubmed:abstractText |
The monoclonal antibody cetuximab (IMC-225, Erbitux) inhibits epidermal growth factor receptor (EGFR) signaling and has been approved for metastatic colon cancer therapy. However, to achieve effective titers, passive antibody therapies must be repeatedly administered over long periods. To overcome this limitation, we aimed to generate a vaccine inducing continuously available "cetuximab-like" antibodies in vivo using the mimotope approach.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Blocking,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/cetuximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1460-2105
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
16
|
|
pubmed:volume |
97
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1663-70
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16288119-Animals,
pubmed-meshheading:16288119-Antibodies, Blocking,
pubmed-meshheading:16288119-Antibodies, Monoclonal,
pubmed-meshheading:16288119-Antibody-Dependent Cell Cytotoxicity,
pubmed-meshheading:16288119-Antineoplastic Agents,
pubmed-meshheading:16288119-Bacteriophages,
pubmed-meshheading:16288119-Binding Sites, Antibody,
pubmed-meshheading:16288119-Blotting, Western,
pubmed-meshheading:16288119-Breast Neoplasms,
pubmed-meshheading:16288119-Cancer Vaccines,
pubmed-meshheading:16288119-Carcinoma, Squamous Cell,
pubmed-meshheading:16288119-Cell Line, Tumor,
pubmed-meshheading:16288119-DNA, Neoplasm,
pubmed-meshheading:16288119-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:16288119-Epitopes,
pubmed-meshheading:16288119-Female,
pubmed-meshheading:16288119-Humans,
pubmed-meshheading:16288119-Immunization, Passive,
pubmed-meshheading:16288119-Mice,
pubmed-meshheading:16288119-Mice, Inbred BALB C,
pubmed-meshheading:16288119-Microscopy, Fluorescence,
pubmed-meshheading:16288119-Receptor, Epidermal Growth Factor,
pubmed-meshheading:16288119-Research Design,
pubmed-meshheading:16288119-Sequence Analysis, DNA,
pubmed-meshheading:16288119-Signal Transduction,
pubmed-meshheading:16288119-Transfection,
pubmed-meshheading:16288119-Tumor Stem Cell Assay
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
|
|
pubmed:affiliation |
Department of Pathophysiology, Medical University of Vienna, Vienna, Austria.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
